Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lisata Therapeutics (LSTA) Gross Margin (2016 - 2017)

Lisata Therapeutics (LSTA) has disclosed Gross Margin for 8 consecutive years, with 1.51% as the latest value for Q1 2017.

  • For the quarter ending Q1 2017, Gross Margin fell 1835.0% year-over-year to 1.51%, compared with a TTM value of 7.75% through Mar 2017, down 638.0%, and an annual FY2016 reading of 11.76%, up 140.0% over the prior year.
  • Gross Margin was 1.51% for Q1 2017 at Lisata Therapeutics, down from 9.15% in the prior quarter.
  • Across five years, Gross Margin topped out at 19718.99% in Q3 2013 and bottomed at 98737.5% in Q2 2015.
  • Average Gross Margin over 5 years is 24882.6%, with a median of 7.58% recorded in 2016.
  • The sharpest move saw Gross Margin crashed -11705389bps in 2014, then surged 9875254bps in 2016.
  • Year by year, Gross Margin stood at 5.01% in 2013, then tumbled by -1573822bps to 78810.29% in 2014, then skyrocketed by 100bps to 53.93% in 2015, then crashed by -83bps to 9.15% in 2016, then plummeted by -116bps to 1.51% in 2017.
  • Business Quant data shows Gross Margin for LSTA at 1.51% in Q1 2017, 9.15% in Q4 2016, and 7.58% in Q3 2016.